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Abstract
Streptococcus pneumoniae (pneumococcus) is the most common bacterial etiology of community-
acquired pneumonia (CAP) in adults, a leading cause of death. The majority of pneumococcal 
CAP is diagnosed by blood culture, which likely underestimates the burden of disease. The 2007 
CAP guidelines recommend routine use of the rapid pneumococcal urinary antigen (UAg) test. To 
assess the how pneumococcal UAg testing is being used among hospitalized adult CAP patients 
and what barriers restrict its use, a Web-based survey was distributed in 2013 to 1287 infectious 
disease physician members of the Emerging Infectious disease Network of the Infectious Disease 
Society of America. Of 493 eligible responses, 65% use the pneumococcal UAg test. The primary 
barrier to UAg use was availability (46%). UAg users reported ordering fewer other diagnostic 
tests and tailoring antibiotic therapy. Increased access to UAg tests could improve pneumonia 
management and pneumococcal CAP surveillance.
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1. Introduction
Streptococcus pneumoniae (pneumococcus) is the most common bacterial etiology of 
community-acquired pneumonia (CAP) in adults (Klugman et al., 2008), a leading cause of 
morbidity and mortality in the United States (Kung et al., 2008). In recent years, the 
incidence of invasive pneumococcal disease, including bacteremic pneumococcal pneumonia 
in adults, has been declining as a result of routine vaccination of children with 
pneumococcal conjugate vaccines (Pilishvili et al., 2010). The majority of pneumococcal 
pneumonia cases are diagnosed by blood culture. However, because only about 25% of 
pneumococcal pneumonia cases are associated with bacteremia, clinicians miss 
opportunities for a pathogen-specific CAP diagnosis (Said et al., 2013). In addition, the 
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burden of pneumococcal disease and impact of pneumococcal conjugate vaccine are likely 
underestimated (Said et al., 2013). Culture-independent diagnostic tests could improve 
clinical care and non-invasive pneumococcal disease surveillance.
The pneumococcal urinary antigen (UAg) test was licensed by the Food and Drug 
Administration in 1999 and has a reported sensitivity of 50–80% and a specificity of >90% 
(Mandell et al., 2007). The 2007 IDSA/ATS guidelines for the management of CAP 
recommend the routine use of the pneumococcal UAg test as an adjunct to blood cultures for 
hospitalized patients with severe CAP (Mandell et al., 2007). However, physicians do not 
always follow clinical practice guidelines (Cabana et al., 1999). To understand how the 
pneumococcal UAg test is being used in clinical practice and what barriers restrict its use, 
we performed a Web-based survey of practicing infectious disease (ID) physicians regarding 
their use of the pneumococcal UAg test among hospitalized adult patients with CAP.
2. Materials and methods
We surveyed ID physician members of the Infectious Diseases Society of America (IDSA), 
Emerging Infections Network (EIN). The EIN is a provider-based emerging infections 
sentinel network funded by the Centers for Disease Control and Prevention to gather 
information about clinical aspects of infectious diseases (Pillai et al., 2014). An 11-question 
survey was distributed via e-mail or facsimile to 1287 EIN members who care for adult 
patients from the United States, Puerto Rico, and Canada in May 2013. Two reminders were 
sent to non-responders over 3 weeks.
The physicians were asked how frequently they use the pneumococcal UAg test and reasons 
why they do or do not use the test. We also inquired about the clinical setting in which the 
test is used and how results of the pneumococcal UAg test influence clinical decision 
making. For comparison, the survey also asked about use of blood cultures in CAP patients. 
Only respondents who reported that they care for adult hospitalized CAP patients were 
included in the analysis.
A descriptive analysis was performed on completed questions; denominators for certain 
questions varied, as not all physicians responded to all questions. Comparisons between 
groups were made by chi-square analysis using SAS version 9.3. (Cary, NC, USA) P values 
of <0.05 were considered statistically significant.
3. Results
There were 592 (46%) respondents, consistent with other EIN surveys (Gundlapalli et al., 
2013). Characteristics of respondents, including patient population, practice setting, and 
state of residence, did not differ significantly from those of non-respondents. However, 
respondents were significantly more likely than non-respondents to have at least 15 years of 
clinical ID experience (P < 0.001). Ninety-nine responses were excluded because the 
physicians reported that they did not treat hospitalized adult patients with CAP, leaving a 
final sample of 493.
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Of these respondents, 319 (65%) use the pneumococcal UAg test, and 485 (98%) use blood 
cultures in clinical practice. Of the physicians who use the pneumococcal UAg test, 71% had 
access to the test in their clinical lab, and 29% order it as a send-out to another laboratory. 
Respondents who do not use the UAg test (N = 174, 35%) provided several reasons for not 
doing so, including lack of availability (46%), results not available in a timely fashion 
(33%), a belief that results would not influence clinical decision making (32%), perceived 
poor reliability (12%), high cost (9%), and inability to obtain susceptibility results (7%).
We observed wide geographic variations in use of the pneumococcal UAg test (Table 1), 
with highest use in southern regions (range 74–84%) and lower use among northern and 
western regions of the country (range 48–68%). There were no significant differences in 
UAg usage with years of experience since completing ID training. There was a non-
significant (P = 0.06) trend toward differences in UAg usage with community (74%) and 
Veterans Affairs/Department of Defense (72%) hospitals using the UAg test more than 
teaching (60%) and city or county hospitals (60%).
Because blood cultures have been a routine diagnostic method among CAP patients for 
many years, we compared the frequency of UAg testing to blood culture. Among those who 
do use blood cultures or UAg, blood cultures are used more commonly among all patients 
with CAP, whereas UAg testing tends to be used only in selected CAP patients (Table 2).
The UAg is recommended to be used for inpatient settings so we asked physicians about the 
clinical settings in which they use UAg and blood cultures. Of those respondents who use 
these tests, over 93% of respondents order blood cultures, and over 87% of respondents 
order the UAg test for inpatients with CAP. Even greater (P < 0.001) proportions of 
respondents indicated use of these tests for intensive care unit (ICU) patients (Table 2).
Over 80% of respondents who use UAg reported that results influenced clinical decision 
making (Table 2). The most common changes in clinical management related to the ordering 
of fewer other diagnostic tests, narrowing of antibiotic regimens, and shortening of antibiotic 
courses for positive UAg results.
Since ID physicians usually see CAP patients after initial evaluation and management, we 
inquired about respondent’s perception of non-ID physicians’ use of blood cultures and UAg 
(Table 2). Non-ID physicians were perceived to use the UAg test some of the time for CAP 
patients (48%) and blood cultures most of the time or always (69%). Few non-ID physicians 
were perceived to use the UAg always (3%) or most of the time (17%).
4. Discussion
ID diagnostics are shifting from the traditional culture-based methods to culture-independent 
methods such as the pneumococcal UAg test. Our survey indicates that 65% of ID 
physicians use the pneumococcal UAg test routinely; however, they report that <20% of 
non-ID physicians were perceived to use UAg testing most of the time or always. 
Importantly, ID physicians alter clinical management in response to a positive UAg test in 
ways similar to a positive blood culture for S. pneumoniae.
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Improved CAP diagnostic yield may lead to better clinical practice. The recommended 
empiric CAP treatment for inpatients is broad, including either a fluoroquinolone or a third-
generation cephalosporin plus a macrolide, to cover many possible pneumonia-causing 
organisms (Bartlett, 2011). Data support use of β-lactams in adult CAP patients with a 
positive UAg test (Guchev et al., 2005; Stralin et al., 2005), and results from our survey 
indicate that the majority of ID physicians who use the UAg test narrow therapy in response 
to a positive test. The main reasons physicians reported for not using the test were lack of 
ready availability of the UAg test in their clinical settings or lack of timeliness as the test is 
often sent out for analysis. For send-out testing, the delay in result reporting could be up to a 
week, which may be too late to alter treatment. Therefore, healthcare centers could improve 
the quality of care for adult CAP patients with pathogen-directed therapy by making this test 
more available.
Respondents listed potential reasons in the free-text comments of the survey for why UAg is 
not available in their clinical setting and included: cost, extra training due to the Clinical 
Laboratory Improvement Amendments (CLIA), and shelf life of the UAg kit. Regarding 
cost, the UAg test is estimated to cost between $30 and 40 per test in the United States. An 
algorithm to determine cost savings of UAg in Europe 2003 showed that patients started 
empirically on narrow spectrum (less expensive therapy) and used UAg had cost savings of 
~ $9.16 compared to those started empirically on broad spectrum (expensive therapy), which 
had cost excess of ~$27.41 (Oosterheert et al., 2003). However, it is unclear from this study 
how cost savings would be impacted if patients started on empiric therapy subsequently had 
therapy tailored toward pneumococcus after a positive test. Unfortunately, while UAg testing 
is rapid and easy to use, CLIA restricts use to trained technicians in a CLIA-certified 
laboratory. Lastly, the shelf life of the UAg kit is at least 2 years. We suggest that the UAg 
test could be integrated into electronic medical order sets to increase clinical use and results 
of this survey be considered in future CAP clinical guidelines to routinely recommend UAg 
testing for all CAP patients.
Current pneumococcal surveillance depends on culture-based methods (Williams et al., 
2011). Non-bacteremic pneumococcal pneumonia is often not diagnosed with culture-based 
methods. Therefore, the burden of non-bacteremic pneumococcal pneumonia is difficult to 
estimate but is clearly larger than the burden of bacteremic pneumococcal pneumonia (Said 
et al., 2013). Culture-independent tests, such as the pneumococcal UAg test, may be an 
important tool to incorporate into surveillance systems to better estimate the burden of 
pneumococcal pneumonia.
Results of the survey should be interpreted with consideration of important limitations. The 
46% of individuals who responded to our survey may not be representative of those who did 
not respond. The EIN is limited to ID physicians who belong to IDSA and is not 
representative of all physicians. Non-ID clinicians are usually the first to start the evaluation 
of hospitalized CAP patients and were not surveyed directly. In addition, respondents’ 
reported use of the UAg test may differ from their actual practice.
Inappropriate antibiotic use with cephalosporins and macrolides has contributed to emerging 
antibiotic resistance for pneumococci (Hicks et al., 2011); thus, pathogen-specific CAP 
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diagnosis remains critical. While a positive UAg test does not provide susceptibility results, 
it can reassure clinicians that other pathogens (e.g., Staphylococcus aureus) requiring 
broader-spectrum therapy are less likely to be playing a role in a particular patient’s illness. 
Our survey suggests that physicians with access to the test are using rapid culture-
independent diagnostics for hospitalized adult CAP patients more frequently. We suggest 
that use of the UAg test would improve quality of care by allowing clinicians to use more 
targeted therapy and may be incorporated into population-based surveillance systems to 
better estimate the burden of non-bacteremic pneumococcal CAP.
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Table 1
Reported usage and availability of the pneumococcal UAg test by region, clinical experience, and hospital 
type.
Total responded, N = 493 
(38%)
UAg usage, N = 319 
(65%)
UAg available in clinical 
lab, N = 217 (68%)
UAg available as send-
out test, N = 87 (27%)
Region, N (%)
 East South Central 19 (33) 16 (84) 12 (75) 3 (19)
 South Atlantic 75 (33) 62 (83) 38 (61) 23 (37)
 West South Central 34 (40) 25 (74) 15 (60) 9 (36)
 East North Central 76 (40) 52 (68) 43 (83) 8 (15)
 Mountain 34 (47) 23 (68) 18 (78) 5 (22)
 New England 40 (43) 26 (65) 18 (69) 7 (27)
 West North Central 50 (40) 31 (62) 23 (74) 6 (19)
 Mid Atlantic 76 (39) 44 (58) 33 (75) 5 (11)
 Pacific 80 (36) 38 (48) 16 (42) 22 (58)
 Canada 8 (38) 2 (25) 1 (50) 1 (50)
Years since ID fellowship, N (%)
 <5 117 (38) 81 (69) 55 (68) 21 (26)
 5–14 112 (29) 75 (67) 50 (67) 21 (28)
 15–24 129 (43) 74 (57) 49 (66) 22 (30)
 ≥25 134 (47) 89 (66) 63 (71) 23 (26)
Primary hospital type, N (%)
 Community 147 (38) 109 (74) 75 (69) 28 (26)
 VA/DOD hospital 32 (39) 23 (72) 13 (57) 9 (39)
 Non-university teaching 143 (40) 88 (62) 66 (75) 19 (22)
 City/county hospital 20 (53) 12 (60) 5 (42) 6 (50)
 University 149 (36) 86 (57) 57 (66) 25 (29)
 Other 2 (14) 1 (50) 1 (100) 0 (0)
VA = Veterans Affairs; DOD = Department of Defense.
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Table 2
Use of blood culture and pneumococcal UAg test for adult patients with CAP.
Blood culture (%) UAg test (%) P-value
Do you order blood cultures or the pneumococcal UAg test for patients with CAP in your clinical practice?
 Yes 485 (98) 319 (65) <0.001
Of those who use the test, where is the test used?a
 Outpatient 75 (16) 48 (15) 0.918
 Inpatient, non-ICU 445 (93) 271 (87) 0.005
 Inpatient, ICU 469 (98) 299 (96) 0.089
 Other 17 (4) 13 (4) 0.657
Of those who use the test, which patients are tested?a
 All CAP patients 306 (64) 133 (42) <0.001
 The majority of CAP patients 133 (28) 109 (35) 0.034
 Only certain CAP patients, i.e., ICU 41 (9) 64 (20) <0.001
 Other 1 (<1) 8 (3) 0.002
How do results influence clinical management for a positive result?b
 Narrow antibiotic regimen 433 (90) 262 (84) 0.012
 Shorten antibiotic course 117 (24) 88 (28) 0.219
 Order fewer diagnostic tests 304 (63) 209 (67) 0.266
 No change in clinical management 7 (1) 10 (3) 0.096
 Other 32 (7) 6 (2) 0.002
How often do non-ID clinicians use these tests for patients with CAP?c
 Always 65 (13) 12 (3) <0.001
 Most of the time 275 (56) 76 (17) <0.001
 Some of the time 142 (29) 213 (48) <0.001
 Not at all 6 (1) 125 (28) <0.001
 Not sure 1 (<1) 14 (3) <0.001
a
Responses varied for blood culture (N = 479) and UAg (N = 312).
b
Responses varied for blood culture (N = 480) and UAg (N = 311).
c
Responses varied for blood culture (N = 489) and UAg (N = 440).
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